CR7830A - Quinolinil-pirrolopirazoles - Google Patents
Quinolinil-pirrolopirazolesInfo
- Publication number
- CR7830A CR7830A CR7830A CR7830A CR7830A CR 7830 A CR7830 A CR 7830A CR 7830 A CR7830 A CR 7830A CR 7830 A CR7830 A CR 7830A CR 7830 A CR7830 A CR 7830A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pirrolopirazoles
- quinolinil
- quinolinylpyrazole
- tgf
- inhibitors
- Prior art date
Links
- FHPLXZDRNSGYSK-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)quinoline Chemical class N1N=CC=C1C1=CC=C(C=CC=C2)C2=N1 FHPLXZDRNSGYSK-UHFFFAOYSA-N 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a nuevos compuestos de quinolinilpirazol y a su uso como agentes farmaceuticos, particularmente a su uso como inhibidores de la transduccion de senal de TGF-beta
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42889302P | 2002-11-22 | 2002-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7830A true CR7830A (es) | 2005-06-20 |
Family
ID=32393478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7830A CR7830A (es) | 2002-11-22 | 2005-05-06 | Quinolinil-pirrolopirazoles |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7265225B2 (es) |
| EP (1) | EP1565471B1 (es) |
| JP (1) | JP4542906B2 (es) |
| KR (1) | KR101057282B1 (es) |
| CN (1) | CN100345852C (es) |
| AT (1) | ATE341550T1 (es) |
| AU (1) | AU2003291643B2 (es) |
| BR (1) | BR0315337A (es) |
| CA (1) | CA2501322C (es) |
| CO (1) | CO5570677A2 (es) |
| CR (1) | CR7830A (es) |
| CY (1) | CY1106283T1 (es) |
| DE (1) | DE60308893T2 (es) |
| DK (1) | DK1565471T3 (es) |
| EA (1) | EA008387B1 (es) |
| EC (1) | ECSP055807A (es) |
| EG (1) | EG25822A (es) |
| ES (1) | ES2273046T3 (es) |
| HK (1) | HK1081948A1 (es) |
| HR (1) | HRP20050436B1 (es) |
| IL (1) | IL168190A (es) |
| MX (1) | MXPA05005432A (es) |
| NO (1) | NO331403B1 (es) |
| NZ (1) | NZ538942A (es) |
| PL (1) | PL227840B1 (es) |
| PT (1) | PT1565471E (es) |
| UA (1) | UA80571C2 (es) |
| WO (1) | WO2004048382A1 (es) |
| ZA (1) | ZA200503121B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050659A1 (en) * | 2002-11-27 | 2004-06-17 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
| BRPI0613639A2 (pt) * | 2005-07-22 | 2012-02-22 | Lilly Co Eli | composto, composição farmacêutica, uso do composto, e, processo para produzir um composto |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| PL2083863T3 (pl) | 2006-10-03 | 2015-08-31 | Genzyme Corp | Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej |
| CA2666603C (en) * | 2006-10-16 | 2013-08-06 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions |
| JP5984218B2 (ja) | 2010-07-02 | 2016-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体 |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| KR20140027295A (ko) | 2011-04-21 | 2014-03-06 | 길리애드 사이언시즈, 인코포레이티드 | 벤조티아졸 화합물 및 이들의 약학적 용도 |
| US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
| WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| PE20141558A1 (es) | 2012-04-20 | 2014-11-06 | Gilead Sciences Inc | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih |
| EA039595B1 (ru) | 2012-10-05 | 2022-02-15 | Кадмон Корпорейшн, Ллк | Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела |
| WO2014072517A1 (en) | 2012-11-12 | 2014-05-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| EP3277673B1 (en) | 2015-04-01 | 2022-05-04 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
| KR20180094036A (ko) | 2015-12-15 | 2018-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cxcr4 수용체 길항제 |
| US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
| WO2018165979A1 (zh) * | 2017-03-17 | 2018-09-20 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物 |
| US10995083B2 (en) | 2017-03-21 | 2021-05-04 | Hangzhou Solipharma Co., Ltd. | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| US12049475B2 (en) | 2018-07-23 | 2024-07-30 | Brise Pharmaceuticals Co., Ltd. | Bisphosphonate drug conjugates |
| CA3117838A1 (en) | 2018-12-27 | 2020-07-02 | Nexys Therapeutics, Inc. | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
| US20220177978A1 (en) | 2019-04-02 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| CN113557236B (zh) * | 2019-06-10 | 2022-05-10 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| JP2023514324A (ja) | 2020-02-19 | 2023-04-05 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE267830T1 (de) * | 1999-08-27 | 2004-06-15 | Abbott Lab | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen |
| DK1397364T3 (da) * | 2001-05-24 | 2007-11-26 | Lilly Co Eli | Hidtil ukendte pyrrolderivater som farmaceutiske midler |
| AU2003298611A1 (en) | 2002-11-21 | 2004-06-18 | Eli Lilly And Company | Mixed lineage kinase modulators |
-
2003
- 2003-10-11 UA UAA200504767A patent/UA80571C2/uk unknown
- 2003-11-10 DE DE60308893T patent/DE60308893T2/de not_active Expired - Lifetime
- 2003-11-10 DK DK03768531T patent/DK1565471T3/da active
- 2003-11-10 EA EA200500859A patent/EA008387B1/ru not_active IP Right Cessation
- 2003-11-10 AU AU2003291643A patent/AU2003291643B2/en not_active Ceased
- 2003-11-10 EP EP03768531A patent/EP1565471B1/en not_active Expired - Lifetime
- 2003-11-10 AT AT03768531T patent/ATE341550T1/de active
- 2003-11-10 PL PL376797A patent/PL227840B1/pl unknown
- 2003-11-10 WO PCT/US2003/032747 patent/WO2004048382A1/en active IP Right Grant
- 2003-11-10 NZ NZ538942A patent/NZ538942A/en not_active IP Right Cessation
- 2003-11-10 US US10/531,237 patent/US7265225B2/en not_active Expired - Fee Related
- 2003-11-10 ES ES03768531T patent/ES2273046T3/es not_active Expired - Lifetime
- 2003-11-10 CN CNB2003801038400A patent/CN100345852C/zh not_active Expired - Fee Related
- 2003-11-10 MX MXPA05005432A patent/MXPA05005432A/es active IP Right Grant
- 2003-11-10 CA CA2501322A patent/CA2501322C/en not_active Expired - Fee Related
- 2003-11-10 JP JP2004555329A patent/JP4542906B2/ja not_active Expired - Fee Related
- 2003-11-10 PT PT03768531T patent/PT1565471E/pt unknown
- 2003-11-10 BR BR0315337-1A patent/BR0315337A/pt active Pending
- 2003-11-10 KR KR1020057009199A patent/KR101057282B1/ko not_active IP Right Cessation
-
2005
- 2005-04-18 ZA ZA200503121A patent/ZA200503121B/en unknown
- 2005-04-21 IL IL168190A patent/IL168190A/en active IP Right Grant
- 2005-05-06 CR CR7830A patent/CR7830A/es unknown
- 2005-05-16 HR HRP20050436AA patent/HRP20050436B1/hr not_active IP Right Cessation
- 2005-05-18 CO CO05048136A patent/CO5570677A2/es active IP Right Grant
- 2005-05-18 EG EGNA2005000237 patent/EG25822A/xx active
- 2005-05-19 EC EC2005005807A patent/ECSP055807A/es unknown
- 2005-06-21 NO NO20053045A patent/NO331403B1/no not_active IP Right Cessation
-
2006
- 2006-02-16 HK HK06102038A patent/HK1081948A1/xx not_active IP Right Cessation
- 2006-12-08 CY CY20061101769T patent/CY1106283T1/el unknown
-
2007
- 2007-07-25 US US11/782,659 patent/US7834029B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR7830A (es) | Quinolinil-pirrolopirazoles | |
| ECSP034859A (es) | Nuevos derivados de pirrol como agentes farmacéuticos | |
| CY2017048I1 (el) | Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης | |
| UY28623A1 (es) | Derivados de pirazol y usos de los mismos | |
| DE602004008303D1 (de) | Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 | |
| CR8312A (es) | Nuevas sulfonamidas como agentes fitosanitarios | |
| AR028576A1 (es) | Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa | |
| EE200300459A (et) | Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena | |
| AR028575A1 (es) | Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa | |
| BRPI0412404A (pt) | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| CR8193A (es) | Piperazina con o sustituida de grupos feniles y su uso como inhibidores de glyt 1 | |
| ECSP12006640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
| SV2006002232A (es) | Inhibidores bace ref. x-16940 | |
| AR027967A1 (es) | Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos | |
| BRPI0515518A (pt) | análogos de loxapina e métodos de usos dos mesmos | |
| HN2007000437A (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| DK1542970T3 (da) | Pyrrolidinderivater som MAOB-inhibitorer | |
| MXPA03001848A (es) | Derivados de fenoxibencilamina como inhibidores de la reabsorcion de serotonina. | |
| CL2004001678A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos. | |
| DE60328978D1 (de) | Isochinolinderivate als mao-b inhibitoren | |
| ATE430726T1 (de) | N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b | |
| UY30801A1 (es) | Compuestos calciliticos | |
| PT1395553E (pt) | Derivados de pirrolidina como inibidores do factor xa | |
| UY29141A1 (es) | Inhibidores de la adenilato ciclasa soluble |